Highbridge Capital Management LLC raised its position in shares of Danaher Corporation (NYSE:DHR) by 84.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,689 shares of the conglomerate’s stock after acquiring an additional 100,202 shares during the period. Highbridge Capital Management LLC’s holdings in Danaher were worth $18,760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. ETRADE Capital Management LLC raised its holdings in shares of Danaher by 5.1% during the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock worth $1,610,000 after acquiring an additional 917 shares in the last quarter. Honeywell International Inc. purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $25,317,000. Roundview Capital LLC raised its holdings in shares of Danaher by 2.0% during the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock worth $2,167,000 after acquiring an additional 502 shares in the last quarter. Eastern Bank raised its holdings in shares of Danaher by 4,291.1% during the 2nd quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock worth $10,802,000 after acquiring an additional 125,086 shares in the last quarter. Finally, Perkins Coie Trust Co raised its holdings in shares of Danaher by 2.0% during the 2nd quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock worth $2,484,000 after acquiring an additional 586 shares in the last quarter. 76.32% of the stock is currently owned by institutional investors and hedge funds.
In other Danaher news, Director Donald J. Ehrlich sold 10,578 shares of the company’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the transaction, the director now owns 104,621 shares of the company’s stock, valued at approximately $9,501,679.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Robert S. Lutz sold 11,189 shares of the company’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now directly owns 18,314 shares in the company, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock worth $25,218,813 in the last ninety days. 12.20% of the stock is currently owned by corporate insiders.
Danaher Corporation (DHR) opened at $93.18 on Monday. The company has a market capitalization of $64,816.49, a price-to-earnings ratio of 23.95, a price-to-earnings-growth ratio of 2.22 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00. Danaher Corporation has a 12-month low of $77.45 and a 12-month high of $94.82.
Danaher (NYSE:DHR) last announced its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. Danaher’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.87 EPS. equities research analysts expect that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is presently 16.52%.
Several analysts recently weighed in on the company. Robert W. Baird increased their price target on Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Credit Suisse Group increased their price target on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Morgan Stanley increased their price target on Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 20th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a report on Thursday, October 5th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $95.00 price target on shares of Danaher in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $93.31.
ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/12/11/danaher-corporation-dhr-holdings-lifted-by-highbridge-capital-management-llc.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.